PMID- 27773891
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20220330
IS  - 1881-7823 (Electronic)
IS  - 1881-7815 (Linking)
VI  - 10
IP  - 5
DP  - 2016 Nov 15
TI  - Ferulic acid prevents liver injury induced by Diosbulbin B and its mechanism.
PG  - 386-391
AB  - The rhizome of Dioscorea bulbifera Linn, traditionally used to treat thyroid 
      disease and cancer in China, is reported to induce serious liver injury during 
      clinical practice. Diosbulbin B (DB), a diterpene lactone, has been found to be 
      the main toxic compound in D. bulbifera. The present study aims to investigate 
      the protection of ferulic acid (FA) against DB-induced acute liver injury and its 
      engaged mechanism. Mice were orally administered FA (20, 40, 80 mg/kg) once daily 
      for 6 consecutive days; and then orally given DB (250 mg/kg) on the last day. 
      Daily FA (40, 80 mg/kg) decreased DB (250 mg/kg)-induced increase in serum levels 
      of alanine/aspartate aminotransferase (ALT/AST) and alkaline phosphatase (ALP). 
      Histological evaluation showed that FA (80 mg/kg) ameliorated DB-induced 
      hepatocellular degeneration and lymphocyte infiltration. Results of terminal dUTP 
      nick-end labeling (TUNEL) staining assay showed that FA (80 mg/kg) decreased the 
      DB-increased number of apoptotic hepatocytes. FA (40, 80 mg/kg) reduced 
      DB-increased liver malondialdehyde (MDA) amount. FA (40, 80 mg/kg) decreased 
      DB-increased serum levels of tumor necrosis factor alpha (TNF-alpha) and interferon-gamma 
      (IFN-gamma), and liver myeloperoxidase (MPO) activity. FA (80 mg/kg) reversed the 
      DB-induced decrease in expression of inhibitor of kappa B (IkappaB) and the increase 
      in nuclear translocation of the p65 subunit of nuclear factor kappa B (NFkappaBp65). 
      Taken together, our results demonstrate that FA prevents DB-induced acute liver 
      injury via inhibiting intrahepatic inflammation and liver apoptosis.
FAU - Niu, Chengwei
AU  - Niu C
AD  - hanghai Key Laboratory of Complex Prescription, The MOE Key Laboratory for 
      Standardization of Chinese Medicines, and The SATCM Key Laboratory for New 
      Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese 
      Materia Medica, Shanghai University of Traditional Chinese Medicine.
FAU - Sheng, Yuchen
AU  - Sheng Y
FAU - Zhu, Enyuan
AU  - Zhu E
FAU - Ji, Lili
AU  - Ji L
FAU - Wang, Zhengtao
AU  - Wang Z
LA  - eng
PT  - Journal Article
DEP - 20161023
PL  - Japan
TA  - Biosci Trends
JT  - Bioscience trends
JID - 101502754
RN  - 0 (Coumaric Acids)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - 0 (NF-kappa B)
RN  - 20086-06-0 (diosbulbin B)
RN  - 82115-62-6 (Interferon-gamma)
RN  - AVM951ZWST (ferulic acid)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Alanine Transaminase/blood
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Aspartate Aminotransferases/metabolism
MH  - Chemical and Drug Induced Liver Injury/metabolism/*prevention & control
MH  - Coumaric Acids/*therapeutic use
MH  - Heterocyclic Compounds, 4 or More Rings/*toxicity
MH  - Interferon-gamma/metabolism
MH  - Liver/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - NF-kappa B/metabolism
EDAT- 2016/10/25 06:00
MHDA- 2017/01/31 06:00
CRDT- 2016/10/25 06:00
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
AID - 10.5582/bst.2016.01152 [doi]
PST - ppublish
SO  - Biosci Trends. 2016 Nov 15;10(5):386-391. doi: 10.5582/bst.2016.01152. Epub 2016 
      Oct 23.